proxyvotesnow.com

Home › Companies › TRAVERE THERAPEUTICS INC. › 2023-2024

TRAVERE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and TRAVERE THERAPEUTICS INC.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 13Ballot items
  • 179Asset managers
  • 2,524Fund votes
  • 2024-05-08Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore TRAVERE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by TRAVERE THERAPEUTICS INC.

These tallies are TRAVERE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

TRAVERE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-05-08
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Roy D. Baynes, M.D., Ph.D. 55,967,609---- 2,718,5034,018,872 Majority: yes
Elect Director: Suzanne Bruhn, Ph.D. 56,267,040---- 2,419,0724,018,872 Majority: yes
Elect Director: Timothy Coughlin 56,365,805---- 2,320,3074,018,872 Majority: yes
Elect Director: Eric Dube, Ph.D. 56,468,811---- 2,217,3014,018,872 Majority: yes
Elect Director: Gary Lyons 56,039,047---- 2,647,0654,018,872 Majority: yes
Elect Director: Jeffrey Meckler 55,841,370---- 2,844,7424,018,872 Majority: yes
Elect Director: John A. Orwin 43,710,299---- 14,975,8134,018,872 Majority: yes
Elect Director: Sandra Poole 56,051,666---- 2,634,4464,018,872 Majority: yes
Elect Director: Ron Squarer 52,269,791---- 6,416,3214,018,872 Majority: yes
Elect Director: Ruth Williams-Brinkley 54,959,617---- 3,726,4954,018,872 Majority: yes
Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000 36,375,36722,098,658212,086 --4,018,872 Majority: yes
Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers 55,789,5262,854,50642,079 --4,018,872 Majority: yes
Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent registered public accounting firm for the fisc 60,467,7742,184,77552,434 ---- Majority: yes

Source: TRAVERE THERAPEUTICS INC., Form 8-K — read the filing on EDGAR.

How asset managers voted at the TRAVERE THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 179 asset managers that disclosed a TRAVERE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 55,789,526AGAINST: 2,854,506

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 55,789,526 for, 2,854,506 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 73% for, 4% against (77% of the company cast a for/against vote).

The 176 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%
FOR: 95.5%AGAINST: 4.5%ABSTAIN: 0.0%
Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
State Street9,719,3520 00For
Deep Track Capital, LP7,370,0000 00For
BlackRock6,528,7760 00For
Vanguard6,160,5150 00For
Delaware/Macquarie3,582,2370 00For
Rock Springs Capital Management LP3,373,1540 00For
ARMISTICE CAPITAL, LLC01,756,510 00Against
Finepoint Capital LP1,649,2210 00For
Fidelity1,243,8950 00For
EMERALD MUTUAL FUND ADVISERS TRUST1,185,6680 00For
Kynam Capital Management, LP1,177,3700 00For
GEODE CAPITAL MANAGEMENT, LLC1,120,5880 00For
PICTET ASSET MANAGEMENT SA1,116,4320 00For
Charles Schwab1,110,0740 00For
DE Shaw1,032,5280 00For
Eversept Partners, LP955,6180 00For
JACOBS LEVY EQUITY MANAGEMENT, INC875,3460 00For
Renaissance861,5850 00For
EMERALD ADVISERS, LLC733,9700 00For
Nuveen730,4660 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Two Sigma661,2580 00For
JPMorgan132624,056 00Against
Northern Trust575,80042 00For

Showing the 25 largest of 176 asset managers. See all 176 in the interactive database.

2. TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 2,700,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%AGAINST 38%
FOR: 36,375,367AGAINST: 22,098,658

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereun”): 36,375,367 for, 22,098,658 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 47.8% for, 29% against (77% of the company cast a for/against vote).

The 60 asset managers below cast 58% of the shares they voted on this item FOR (15,296,122 for, 11,036,750 against).

FOR 58%AGAINST 42%
FOR: 15,296,122 (57.9%)AGAINST: 11,036,750 (41.8%)ABSTAIN: 71,384 (0.3%)
Largest asset managers voting on “TO APPROVE THE COMPANY'S 2018 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON ST” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,925,61438,300 00For
State Street4,1034,168,627 00Against
Delaware/Macquarie03,582,237 00Against
BlackRock3,525,1310 00For
Kynam Capital Management, LP1,177,3700 00For
Fidelity1,151,34118,000 00For
Eversept Partners, LP0955,618 00Against
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal462,0368,446 00For
Columbia Threadneedle0422,969 00Against
Direxion Shares ETF Trust0401,636 00Against
DWS0271,275 00Against
JPMorgan253,6460 00For
John Hancock0222,488 00Against
Lincoln Financial22,267193,018 00Against
Voya0184,056 00Against
Equitable183,4290 00For
Palo Alto Investors LP110,7190 00For
ProShares0106,459 00Against
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed068,843 00Against
Dimensional052,982 00Against

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

3. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Eric Dube

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 56,468,811WITHHELD: 2,217,301

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Eric Dube, Ph.D.”): 56,468,811 for, 2,217,301 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,136,241 for, 0 against).

FOR 99.8%
FOR: 24,136,241 (99.9%)ABSTAIN: 24,308 (0.1%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

4. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Gary Lyons

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 56,039,047WITHHELD: 2,647,065

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gary Lyons”): 56,039,047 for, 2,647,065 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,123,293 for, 0 against).

FOR 99.8%
FOR: 24,123,293 (99.8%)ABSTAIN: 37,256 (0.2%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

5. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Jeffrey Meckler

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 55,841,370WITHHELD: 2,844,742

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Meckler”): 55,841,370 for, 2,844,742 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 73% for, 4% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,114,088 for, 0 against).

FOR 99.8%
FOR: 24,114,088 (99.8%)ABSTAIN: 46,461 (0.2%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,171,7360 9940For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

6. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: John Orwin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 43,710,299WITHHELD: 14,975,813

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John A. Orwin”): 43,710,299 for, 14,975,813 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 57% for, 20% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (14,717,890 for, 0 against).

FOR 61%ABSTAIN 39%
FOR: 14,717,890 (60.9%)ABSTAIN: 9,442,659 (39.1%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street9,2050 4,163,5250Abstain
Delaware/Macquarie00 3,582,2370Abstain
BlackRock3,525,1310 00For
Fidelity1,098,0400 71,3010For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab00 555,0370Abstain
Principal470,2240 2580For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS00 271,2750Abstain
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial22,2670 193,0180Abstain
Voya00 184,0560Abstain
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI00 89,0100Abstain
Waddell & Reed00 68,8430Abstain
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

7. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ron Squarer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%
FOR: 52,269,791WITHHELD: 6,416,321

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Squarer”): 52,269,791 for, 6,416,321 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 69% for, 8% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (20,280,843 for, 0 against).

FOR 84%ABSTAIN 16%
FOR: 20,280,843 (83.9%)ABSTAIN: 3,879,706 (16.1%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie00 3,582,2370Abstain
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial85,8670 129,4180Abstain
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed00 68,8430Abstain
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

8. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Roy Baynes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 55,967,609WITHHELD: 2,718,503

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes, M.D., Ph.D.”): 55,967,609 for, 2,718,503 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 4% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,061,106 for, 0 against).

FOR 99.5%
FOR: 24,061,106 (99.6%)ABSTAIN: 99,443 (0.4%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,171,7360 9940For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional00 52,9820Abstain
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

9. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ruth Williams-Brinkley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 54,959,617WITHHELD: 3,726,495

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ruth Williams-Brinkley”): 54,959,617 for, 3,726,495 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 72% for, 5% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (23,365,548 for, 0 against).

FOR 97%
FOR: 23,365,548 (96.7%)ABSTAIN: 795,001 (3.3%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab00 555,0370Abstain
Principal470,2240 2580For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI00 89,0100Abstain
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments00 52,8340Abstain
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

10. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Sandra Poole

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 56,051,666WITHHELD: 2,634,446

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sandra Poole”): 56,051,666 for, 2,634,446 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,114,088 for, 0 against).

FOR 99.8%
FOR: 24,114,088 (99.8%)ABSTAIN: 46,461 (0.2%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,171,7360 9940For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

11. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Suzanne Bruhn

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 56,267,040WITHHELD: 2,419,072

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Suzanne Bruhn, Ph.D.”): 56,267,040 for, 2,419,072 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,136,014 for, 0 against).

FOR 99.8%
FOR: 24,136,014 (99.9%)ABSTAIN: 24,535 (0.1%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

12. To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Timothy Coughlin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 56,365,805WITHHELD: 2,320,307

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Timothy Coughlin”): 56,365,805 for, 2,320,307 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,111,101 for, 0 against).

FOR 99.7%
FOR: 24,111,101 (99.8%)ABSTAIN: 49,448 (0.2%)
Largest asset managers voting on “To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for ” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,2330 4970For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,2240 2580For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

13. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 60,467,774AGAINST: 2,184,775

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent regist”): 60,467,774 for, 2,184,775 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,108,829 outstanding shares: 79% for, 3% against (82% of the company cast a for/against vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (24,136,738 for, 0 against).

FOR 99.9%
FOR: 24,136,738 (99.9%)ABSTAIN: 23,811 (0.1%)
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at TRAVERE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,963,9140 00For
State Street4,172,7300 00For
Delaware/Macquarie3,582,2370 00For
BlackRock3,525,1310 00For
Fidelity1,169,3410 00For
TIAA728,2280 00For
FINANCIAL INVESTORS TRUST698,1680 00For
Charles Schwab555,0370 00For
Principal470,4820 00For
Columbia Threadneedle422,9690 00For
Direxion Shares ETF Trust401,6360 00For
DWS271,2750 00For
JPMorgan253,6460 00For
John Hancock222,4880 00For
Lincoln Financial215,2850 00For
Voya184,0560 00For
Equitable183,4290 00For
ProShares106,4590 00For
QUANTITATIVE MASTER SERIES LLC101,9460 00For
SEI89,0100 00For
Waddell & Reed68,8430 00For
Dimensional52,9820 00For
ALPS ETF Trust52,9190 00For
Russell Investments52,8340 00For
Brighthouse28,7180 23,8110For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Largest TRAVERE THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of TRAVERE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 76,108,829 shares outstanding at the time of that meeting.

Top TRAVERE THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1State Street 12.77%
2Deep Track Capital, LP 9.68%
3BlackRock 8.58%
4Vanguard 8.09%
5Delaware/Macquarie 4.71%
6Rock Springs Capital Management LP 4.43%
7ARMISTICE CAPITAL, LLC 2.31%
8Finepoint Capital LP 2.17%
9Fidelity 1.63%
10EMERALD MUTUAL FUND ADVISERS TRUST 1.56%

Reported TRAVERE THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

TRAVERE THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 10.64% 13F
Deep Track Capital, LP 9.88% DEF14A
Armistice Capital, LLC 9.70% DEF14A
Vanguard Group 8.69% 13F
State Street 8.68% 13F
Macquarie Group Limited 6.24% DEF14A
Morgan Stanley 5.46% DEF14A
FMR (Fidelity) 3.80% 13F
Renaissance Technologies 3.76% 13F
Millennium Management 2.89% 13F

Percentages above are of 76,108,829 shares outstanding, as reported by TRAVERE THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TRAVERE THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At TRAVERE THERAPEUTICS INC.'s shareholder meeting held 2024-05-08, in the 2023-2024 proxy season, 179 asset managers reported how they voted on 13 ballot items in their SEC Form N-PX filings, covering 2,524 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: TRAVERE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

TRAVERE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.